Diebold (DBD) PT Raised to $6.50 at JPMorgan

February 13, 2019 1:23 PM EST
Get Alerts DBD Hot Sheet
Price: $11.40 +1.51%

Rating Summary:
    6 Buy, 7 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 12 | New: 23
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

JPMorgan analyst Paul Coster established the price target on Diebold (NYSE: DBD) at $6.50 while maintaining a Underweight rating.

As a reminder, DBD reported 2018 fourth quarter and full year financial results earlier today before the market opened. Highlights of the earnings report:

  • • Q4 revenue of $1.3 billion increased 3.2% on an as-reported basis, or 6.6% in constant currency; full-year revenue was $4.6 billion, flat on an as-reported basis, down 1.8% in constant currency
  • Q4 GAAP EPS attributable to Diebold Nixdorf was a loss of $1.62, or a loss of $0.08 per share on a non-GAAP basis; full-year GAAP EPS attributable to Diebold Nixdorf was a loss of $7.48, or loss of $1.03 on a non-GAAP basis
  • Net loss for Q4 was $127.5 million; adjusted EBITDA in Q4 was $126.7 million, an increase of 20.9% from the prior year quarter
  • Net cash provided by operating activities was $268.0 million in Q4 and a use of $104.1 million for the full year; free cash flow was $250.0 million in Q4 and a use of cash of $162.6 million for the full year
  • DN Now initiatives and stable market demand drive improved financial outlook for 2019

Shares of DBD trade up +38.8%, while SPY trades up +0.32% in afternoon trading.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities

JPMorgan, Earnings